Effect of Eltrombopag Plus G-CSF on Human CD34+ Cell Mobilization in Multiple Myeloma Patients Undergoing ASCT
Status:
Completed
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
Eltrombopag may improve the cell collection available for Autologous Stem Cell
Transplant(ASCT). The overall goal is to determine if adding Eltrombopag to the standard ASCT
will increase the number of blood cells collected and reduce the number of times blood needs
to be collected. This study will also determine the highest dose of Eltrombopag that can be
used without causing serious side effects.